Sex differences in the pharmacokinetics of pioglitazone in rats
Sex differences in the pharmacokinetics of pioglitazone in rats
复制标题
DOI：
10.1016/s1532-0456(03)00194-7
复制
发表时间：
2003-09-01
影响因子：
3.9
通讯作者：
Iga, T
中科院分区：
文献类型：
--
作者：
Fujita, Y;Yamada, Y;Iga, T
临床研究表明，吡格列酮（一种胰岛素增敏剂）对女性的作用比对男性的作用更强。为了确定吡格列酮药代动力学的性别差异，我们检测了单次或重复口服吡格列酮（10 mg/kg）治疗的雄性和雌性大鼠中吡格列酮及其活性代谢物（M-II、M-III和M-IV）的血浆和白色脂肪组织水平。吡格列酮的 AUC（149.6 +/- 22.6 vs. 103.3 +/- 14.0 mug.h/ml；P
Clinical studies have suggested that pioglitazone, an insulin sensitizer, has a stronger effect in women than in men. To determine the sex difference in the pharmacokinetics of pioglitazone, we examined the plasma and white adipose tissue levels of pioglitazone and its active metabolites (M-II, M-III and M-IV) in male and female rats treated with a single or repeated oral administration of pioglitazone (10 mg/kg). The AUCs of pioglitazone (149.6 +/- 22.6 vs. 103.3 +/- 14.0 mug.h/ml; P